Methylxanthine treatment for apnea in preterm infants.

@article{Hendersonsmart2001MethylxanthineTF,
  title={Methylxanthine treatment for apnea in preterm infants.},
  author={David J Henderson-smart and Peter A Steer},
  journal={The Cochrane database of systematic reviews},
  year={2001},
  volume={3},
  pages={
          CD000140
        }
}
BACKGROUND Recurrent apnea is common in preterm infants, particularly at very early gestational ages. These episodes of loss of effective breathing can lead to hypoxemia and bradycardia which may be severe enough to require resuscitation including use of positive pressure ventilation. Methylxanthines have been used to stimulate breathing and prevent apnea and its consequences. OBJECTIVES The objective of this review is to determine if methylxanthine treatment in preterm infants with recurrent… Expand
Caffeine versus theophylline for apnea in preterm infants.
TLDR
Caffeine appears to have similar short-term effects on apnea/bradycardia as does theophylline although caffeine has certain therapeutic advantages over theophylla, which is associated with higher rates of toxicity. Expand
Methylxanthine treatment for apnoea in preterm infants.
TLDR
Methylxanthine is effective in reducing the number of apnoeic attacks and the use of mechanical ventilation in the two to seven days after starting treatment, and caffeine is also associated with better longer term outcomes. Expand
Prophylactic methylxanthine for prevention of apnoea in preterm infants.
TLDR
The results of this review do not support the use of prophylactic caffeine for preterm infants at risk of apnoea. Expand
Prophylactic methylxanthines for endotracheal extubation in preterm infants.
TLDR
Methylxanthines increase the chances of successful extubation of preterm infants within one week of age and important neurodevelopmental outcomes are improved by methylxanthine therapy. Expand
Comparison between Caffeine and Theophylline Therapy for Apnea of Prematurity
TLDR
Caffeine was as effective as theophylline in the short­term for reducing apnea in preterm babies and was better tolerated and was easier to administer. Expand
Methylxanthine Therapy for Apnea of Prematurity: Evaluation of Treatment Benefits and Risks at Age 5 Years in the International Caffeine for Apnea of Prematurity (CAP) Trial
TLDR
The main outcome at 5 years will be a composite of death or survival with severe disability in at least one of six domains: cognition, neuromotor function, vision, hearing, behavior, and general health. Expand
Is Aromatherapy Effective for Apnea in Preterm Infants? A Systematic Review
TLDR
Aromatherapy can be effective for apnea in preterm infants, and a subgroup analysis of subjects with a body weight of 2,000 grams or more showed a shorter hospitalization period, when compared by gender. Expand
Caffeine therapy for apnea of prematurity.
TLDR
Caffeine therapy for apnea of prematurity reduces the rate of bronchopulmonary dysplasia in infants with very low birth weight and reduced weight gain temporarily. Expand
Long-term effects of caffeine therapy for apnea of prematurity.
TLDR
Caffeine therapy for apnea of prematurity improves the rate of survival without neurodevelopmental disability at 18 to 21 months in infants with very low birth weight. Expand
[Apnea of prematurity: what's new?].
TLDR
In treated infants, compared with controls, a decreased incidence of the following complications was recorded: bronchopulmonary dysplasia at 36 weeks of conceptional age, patent ductus arteriosus, cerebral palsy at 18 months of age. Expand
...
1
2
3
4
5
...

References

SHOWING 1-9 OF 9 REFERENCES
Caffeine Citrate
TLDR
Caffeine citrate was generally well tolerated by neonates in clinical trials and it decreased the incidence of apnoea of prematurity compared with placebo, and has demonstrated similar efficacy to theophylline, but is generally better tolerated and has a wider therapeutic index. Expand
The efficacy of caffeine in the treatment of recurrent idiopathic apnea in premature infants.
TLDR
No treatment of apnea other than caffeine was required in group I, whereas six neonates in group II had such severe and frequent apneic episodes for more than 48 hours that withholding additional treatment was believed to be unethical and no undesirable side effects of caffeine treatment were observed. Expand
A blinded, randomized, placebo-controlled trial to compare theophylline and doxapram for the treatment of apnea of prematurity.
TLDR
Although therapy with theophylline or doxapram is associated with a significant short-term reduction in the incidence of apnea compared with that in placebo-treated infants, the long-term response to treatment is frequently incomplete and is not sustained more than 1 week. Expand
Methylxanthines and sensorineural outcome at 14 years in children < 1501 g birthweight
TLDR
The aim of this study was to determine the relationship between theophylline therapy and outcome at 14 years of age in surviving preterm children of birthweight < 1501 g. Expand
A Randomized, Controlled, Double-Blind Trial Comparing Two Loading Doses of Aminophylline
TLDR
If a clinical decision to start intravenous aminophylline therapy in preterm infants has been made, the use of an 8 mg/kg loading dose appears to be a better and safe way to quickly achieve serum theophyllines levels within the recommended range. Expand
Caffeine Citrate for the Treatment of Apnea of Prematurity: A Double‐Blind, Placebo‐Controlled Study
TLDR
Evaluation of the efficacy and safety of caffeine citrate for treatment of apnea of prematurity and its use in clinical practice is evaluated. Expand
Results of the First Double Blind Placebo (Pl) Controlled Study of Caffeine Citrate (Cc) for the Treatment of Apnea of Prematurity (Aop) † 1001
Results of the First Double Blind Placebo (Pl) Controlled Study of Caffeine Citrate (Cc) for the Treatment of Apnea of Prematurity (Aop) † 1001